Joseph Michael Tuscano, M.D.
Professor
To see if Joseph Michael Tuscano is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).
Locations and Contact
UC Davis Comprehensive Cancer Center
UC Davis Comprehensive Cancer Center
2279 45th Street
Sacramento, CA 95817
Phone: 916-734-5959
Additional Numbers
Clinic Fax
Clinic Referral Phone
Physician Referrals
Philosophy of Care
Dr. Tuscano believes in high quality, innovative, and compassionate care of his patients. Dr. Tuscano believes in a team-based approach to patient care, utilizing expertise of nurses, pharmacists, social workers, and consultants to provide complete care for his patients.
Clinical Interests
Dr. Tuscano's areas of specialty include the treatment of leukemia, lymphoma, MDS, and multiple myeloma. He is also a member of the adult stem cell transplant team.
Research/Academic Interests
Dr. Tuscano has both basic/translation and clinical research interests that include the development of novel antibody and other immune-based therapeutics for hematologic malignancies.
Division
Hematology and Oncology
Malignant Hematology/Cellular Therapy and Transplantation
Center/Program Affiliation
Stem Cell Transplant Program
UC Davis Comprehensive Cancer Center
Stem Cell Research Program
Undergraduate School
B.S., California State University, Sacramento, Sacramento CA 1985
Medical School
M.D., University of Southern California School of Medicine, Los Angeles CA 1989
Internship
Internal Medicine, UC Davis Medical Center, Sacramento CA 1989-1992
Residency
Internal Medicine, UC Davis Medical Center, Sacramento CA 1989-1992
Fellowship
Hematology/Oncology, National Institutes of Health, National Cancer Institute, Bethesda MD 1992-1996
Fellowship
Hematology/Oncology, UC Davis Medical Center, Sacramento CA 1997-1998
Diamond Doctor award (top 1%) by UC Davis Health, 2021
Top Doctor's award by Sacramento Magazine, 2019, 2020
Distinguished Achievement Award by a California State Assembly Resolution, 2018
Certificate of Appreciation: The Leukemia & Lymphoma Society, 2009
For a comprehensive list of Dr. Tuscano's publications, please click here (opens new window).
Evens AM, Connors JM, Younes A, Ansell SM, Kim WS, Radford J, Feldman T, Tuscano J, Savage KJ, Oki Y, Grigg A, Pocock C, Dlugosz-Danecka M, Fenton K, Forero-Torres A, Liu R, Jolin H, Gautam A, Gallamini A. Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study. Haematologica. 2022 May 1;107(5):1086-1094. doi:10.3324/haematol.2021.278438. PMID:34162178.
Poh C, McPherson JD, Tuscano J, Li Q, Parikh-Patel A, Vogel CFA, Cockburn M, Keegan T. Environmental pesticide exposure and non-Hodgkin lymphoma survival: a population-based study. BMC Med. 2022 Apr 26;20(1):165. doi:10.1186/s12916-022-02348-7. PMID:35468782.
Virk HS, Shahlaie K, Ramani B, Perry A, Fragoso R, Tuscano J, Liu YA. Orbital Rosai-Dorfman Disease Presenting as Optic Neuritis. J Neuroophthalmol. 2022 Mar 1;42(1):e293-e296. doi:10.1097/WNO.0000000000001405. Epub 2021 Nov 19. PMID:35475853.
Othman T, Moskoff BN, Esteghamat N, Hoeg RT, Rosenberg AS, Jonas BA, Abedi M, Richman C, Tuscano JM. Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas. Leuk Lymphoma. 2022 Jan;63(1):231-234. doi:10.1080/10428194.2021.1975190. Epub 2021 Sep 6. PMID:34486920.
Shimoda M, Lyu Y, Wang KH, Kumar A, Miura H, Meckler JF, Davis RR, Chantarasrivong C, Izumiya C, Tepper CG, Nakajima KI, Tuscano J, Barisone G, Izumiya Y. KSHV transactivator-derived small peptide traps coactivators to attenuate MYC and inhibits leukemia and lymphoma cell growth. Commun Biol. 2021 Dec 2;4(1):1330. doi:10.1038/s42003-021-02853-0. PMID:34857874.
Zelenetz AD, Gordon LI, Chang JE, Christian B, Abramson JS, Advani RH, Bartlett NL, Budde LE, Caimi PF, De Vos S, Dholaria B, Fakhri B, Fayad LE, Glenn MJ, Habermann TM, Hernandez-Ilizaliturri F, Hsi E, Hu B, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Lim M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar H. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021. J Natl Compr Canc Netw. 2021 Nov;19(11):1218-1230. doi:10.6004/jnccn.2021.0054. PMID:34781267.
Tuscano JM, Poh C, Kaesberg P, Luxardi G, Merleev A, Marusina A, Brunson A, Rosenberg A, Jonas B, Maverakis E. Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma. Clin Cancer Res. 2021 Sep 1;27(17):4726-4736. doi:10.1158/1078-0432.CCR-20-4622. Epub 2021 Jun 4. PMID:34088724.
Rosenberg AS, Facon T, Parikh K, Chung W, Srinivasan S, Kotey S, Tuscano J. Association of Morbid Progression With Overall Survival Among Patients With Multiple Myeloma: Validation of the Progression-free Survival Endpoint. Clin Lymphoma Myeloma Leuk. 2021 May;21(5):345-354.e4. doi:10.1016/j.clml.2020.12.021. Epub 2020 Dec 27. PMID:33563582.
Kambhampati S, Fakhri B, Ai WZ, Kaplan LD, Tuscano JM, Wieduwilt MJ, Sudhindra A, Cavallone E, Reiner J, Aoun C, Castillo M, Martinelli M, Ta T, Le D, Padilla M, Crawford E, Andreadis CB. Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial. Clin Lymphoma Myeloma Leuk. 2021 Mar;21(3):139-146. doi:10.1016/j.clml.2020.12.020. Epub 2020 Dec 24. PMID:33478921.